Coronavirus vaccine compositions, methods, and uses thereof
AssigneeSichuan Clover Biopharmaceuticals, Inc.
InventorsPeng LIANG, Joshua LIANG
Life of this patent
Estimating the term…
Loading patent…
AssigneeSichuan Clover Biopharmaceuticals, Inc.
InventorsPeng LIANG, Joshua LIANG
Estimating the term…
The present disclosure relates in some aspects to immunogenic compositions including recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing a coronavirus infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.
1-62. (canceled)
A fusion polypeptide comprising a SARS-CoV-2 spike (S) ectodomain polypeptide and a C-propeptide of a human pro-collagen, wherein the C-propeptide is configured to form a disulfide bond-linked homotrimer.
A method of generating an immune response in a subject, comprising administering to the subject an effective amount of a homotrimer of a fusion polypeptide comprising a SARS-CoV-2 spike (S) ectodomain polypeptide and a C-propeptide of a human pro-collagen, wherein the homotrimer comprises interchain disulfide bonds among the C-propeptide sequences, and wherein the immune response is to the SARS-CoV-2 S ectodomain polypeptide or a fragment or epitope thereof.
Dependencies are inferred from the claim text.